Clinical Trial

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Study acronym: HopES
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion of systemic treatment * Clinically advanced sarcoma patients in the salvage treatment setting Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-12-17; most recent amendment 2025-02-21.
Status change: Recruiting → Active, Not Recruiting 2023-01-19
Status change: Not Yet Recruiting → Recruiting 2019-11-07
Trial Details
NCT Number NCT03778996
Lead Sponsor Sarcoma Oncology Research Center, LLC
Collaborators: Tyme, Inc
Conditions Sarcoma, Ewing, Sarcoma
Enrollment 31 participants
Start Date 2020-01-03
Primary Completion 2027-12-19 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-24